

THURSDAY, JAN. 26, 2017

Time	Topic	Speakers
6:30 a.m.	Continental Breakfast	
<b>7:00 a.m. – 10:00 a.m.</b>	<b>Session I: Debates</b>	<b>Moderators: Kenneth Kim, MD, FACOG, FACS, and Linda Duska, MD</b>
7:00 a.m. – 7:10 a.m.	Welcome and Opening Announcements	Winter Meeting Course Directors: John Brown, MD and Wendel Naumann, MD
7:10 a.m. – 7:45 a.m.	Should We Use Sedlis Criteria to Treat All Patients Who Meet the Criteria?	Will Winter, MD and Stephen Rose, MD
7:45 a.m. – 7:55 a.m.	Q & A	
7:55 a.m. – 8:03 a.m.	<b>Presentation 1:</b> Intraperitoneal Versus Intravenous Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Cytoreductive Surgery	Kristin Bixel, MD
8:03 a.m. – 8:05 a.m.	Q & A	
8:05 a.m. – 8:30 a.m.	Coffee Break – View Fellow and Resident Posters	
8:30 a.m. – 9:05 a.m.	Should We Perform Total Hysterectomy at the Time of RR BSO for <i>BRCA</i> + Patients?	Christine Walsh, MD and Chad Hamilton, MD
9:05 a.m. – 9:15 a.m.	Q & A	
9:15 a.m. – 9:50 a.m.	IP Chemo Debate, Part Deux	David O'Malley, MD and Wendel Naumann, MD
9:50 a.m. – 10:00 a.m.	Q & A	
10:00 a.m. – 3:45 p.m.	Open	
3:45 p.m. – 4:00 p.m.	Break & View Posters	
<b>4:00 p.m. – 7:00 p.m.</b>	<b>Session II: PARP Inhibitors for Ovarian Cancer Therapy: The Present and Future of Transformative Care in Gynecologic Cancer (PARPi: Oh the places you should go!)</b> <i>This activity is supported by Clovis Oncology. Content and CME will be provided by SGO</i>	<b>Moderators: Angeles Alvarez-Secord, MD and Ritu Salani, MD</b>
4:00 p.m. – 4:05 p.m.	Introduction of Session II	
4:05 p.m. – 4:40 p.m.	Debate: Appropriate Timing For PARP Inhibitors	Kathleen Moore, MD and Robert Coleman, MD
4:40 p.m. – 4:50 p.m.	Q & A	
4:50 p.m. – 5:25 p.m.	PARP Inhibitors, Reviews of Biomarkers and Safety	Ursula Matulonis, MD
5:25 p.m. – 5:35 p.m.	Q & A	
5:35 p.m. – 5:43 p.m.	<b>Presentation 2:</b> Effect of Estrogen Therapy on Ovarian Tumor Cells Treated with Cisplatin	Georgina Cheng, MD, PhD
5:43 p.m. – 5:45 p.m.	Q & A	
5:45 p.m. – 6:05 p.m.	Break & View Posters	
6:05 p.m. – 6:35 p.m.	Molecular Tumor Board	Stephanie Gaillard, MD, PhD
6:35 p.m. – 6:45 p.m.	Q & A	
6:45 p.m. – 7:00 p.m.	5 (3 min.) Rapid Fire Presentations (Listed on page 3)	
7:00 p.m. – 7:30 p.m.	Resident and Fellow Reception (Invite Only)	
7:30 p.m. – 8:30 p.m.	Industry Supported Symposium Dinner: Advances in the Treatment of Recurrent Ovarian Cancer: A Discussion on Platinum-Sensitive and Platinum-Resistant Ovarian Cancer – Sponsored by Genentech	

FRIDAY, JAN. 27, 2017

Time	Topic	Speakers
6:30 a.m.	Continental Breakfast	
<b>7:00 a.m. – 10:00 a.m.</b>	<b>Session III: Endometrial Cancer</b>	<b>Moderator: Matthew Powell, MD</b>
7:00 a.m. – 7:10 a.m.	Welcome and Opening Announcements	Winter Meeting Course Directors: John Brown, MD and Wendel Nauman, MD
7:10 a.m. – 7:50 a.m.	Update on Therapies for High-Risk and Recurrent Endometrial Carcinoma	Matthew Powell, MD
7:50 a.m. – 7:55 a.m.	Q & A	
7:55 a.m. – 8:35 a.m.	Clinical Trials - How Did We Get Here and What Can We Do	David Mutch, MD
8:35 a.m. – 8:40 a.m.	Q & A	
8:40 a.m. – 9:00 a.m.	Break & View Posters	
9:00 a.m. – 9:08 a.m.	<b>Presentation 3:</b> Preoperative Predictors of Endometrial Cancer at Hysterectomy for Complex Atypical Hyplasia	Blair Smith, MD
9:08 a.m. – 9:10 a.m.	Q & A	
9:10 a.m. – 9:50 a.m.	Future Endometrial Cancer Trials: Projects in Process	B.J. Rimel, MD
9:50 a.m. – 10:00 a.m.	Q & A	
10:00 a.m. – 3:45 p.m.	Open	
3:45 p.m. – 4:00 p.m.	Break & View Posters	
<b>4:00 p.m. – 7:00 p.m.</b>	<b>Session IV: Tumor Board</b>	<b>Moderators: Robert Coleman, MD and Erin Crane, MD, MPH</b> <b>Speakers: Larissa Meyer, MD, Ritu Salani, MD, Bradley Corr, MD, Jay Coleman, MD, and Marilyn Huang, MD</b>
4:00 p.m. – 5:30 p.m.	Tumor Board Presentations	
5:30 p.m. – 5:38 p.m.	<b>Presentation 4:</b> Ovarian Granulosa Cell Tumor: Matched Cohort Analyses for Fertility Preservation and Adjuvant Chemotherapy	Brandon-Luke Seagle, MD
5:38 p.m. – 5:40 p.m.	Q & A	
5:40 p.m. – 6:00 p.m.	Break & View Posters	
6:00 p.m. – 7:00 p.m.	Tumor Board Presentations	
7:00 p.m. – 8:00 p.m.	Networking Reception – Sponsored by Clovis Oncology	

SATURDAY, JAN. 28, 2017

Time	Topic	Speakers
6:30 a.m.	Continental Breakfast	
<b>7:00 a.m. – 10:00 a.m.</b>	<b>Session V: Palliative Care and End of Life Care</b>	<b>Moderator: Floor Backes, MD</b>
7:00 a.m. – 7:05 a.m.	Welcoming and Opening Announcements	Winter Meeting Course Directors: John Brown, MD and Wendel Naumann, MD
7:05 a.m. – 7:35 a.m.	Highlights of ASCO Palliative Care in Oncology Symposium 2016	Carolyn Lefkowitz, MD, MPH, MS
7:35 a.m. – 7:40 a.m.	Q & A	
7:40 a.m. – 8:10 a.m.	Prognostic Awareness and Communications: “Critical Conversations in GYN Oncology”	Kerri Bevis, MD
8:10 a.m. – 8:15 a.m.	Q & A	
8:15 a.m. – 8:35 a.m.	Break & View Posters	
8:35 a.m. – 8:43 a.m.	<b>Presentation 5:</b> Associations Between Disease Dissemination, Surgical Outcome, and Molecular Subtypes in Advanced Ovarian Cancer	Diogo Torres, MD
8:43 a.m. – 8:45 a.m.	Q & A	
8:45 a.m. – 9:15 a.m.	Opioid Use in Cancer Pain: Concepts and Controversies	Chris Lutman, MD
9:15 a.m. – 9:20 a.m.	Q & A	
9:20 a.m. – 9:50 a.m.	Death with Dignity	Michael Pearl, MD
9:50 a.m. – 9:55 a.m.	Q & A	
9:55 a.m. – 10:00 a.m.	Closing Statements	

RAPID FIRE PRESENTATIONS

THURSDAY, JAN. 26, 2017 | 6:45 P.M. – 7:00 P.M.

Time	Topic	Speakers
6:45 p.m. – 6:48 p.m.	Fertility conserving surgery among young women with stage I epithelial ovarian cancer: Analysis of the national cancer data base	Allison Gockley, MD
6:48 p.m. – 6:51 p.m.	Association of hospital proportion of morbidly obese patients on the cost and outcomes of hysterectomy in gynecologic oncology patients	Aimee Rolston, MD
6:51 p.m. – 6:54 p.m.	Validating computerized tomography morphometric ratios in relation to clinical and pathological characteristics in endometrial cancer patients	Felicia Bahadue, MD
6:54 p.m. – 6:57 p.m.	The significance of lymphovascular space invasion in microinvasive squamous cell carcinoma of the vulva	Jason Ricciuti, MD
6:57 p.m. – 7:00 p.m.	Choosing wisely: A cross-sectional survey of gynecologic oncologist practice patterns and concordance with current SGO recommendations	Adam Pyrzak, MD